From Wikipedia, the free encyclopedia
Jump to: navigation, search
Not to be confused with gliclazide or glyburide.
Glipizide ball-and-stick.png
Systematic (IUPAC) name
Clinical data
Trade names Glucotrol
AHFS/ monograph
MedlinePlus a684060
Legal status
  • POM (UK), ℞-only (U.S.)
Routes Oral
Pharmacokinetic data
Bioavailability 100% (regular formulation)
90% (extended release)
Protein binding 98 to 99%
Metabolism Hepatic hydroxylation
Half-life 2 to 5 hours
Excretion Renal and fecal
CAS number 29094-61-9 YesY
ATC code A10BB07
PubChem CID 3478
DrugBank DB01067
ChemSpider 3359 YesY
KEGG D00335 YesY
Chemical data
Formula C21H27N5O4S 
Molecular mass 445.536 g/mol
 N (what is this?)  (verify)

Glipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas.

Originally available in 1984, it is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams. Other companies also market glipizide, most commonly extended release tablets of 5 and 10 milligrams.

Mechanism of Action[edit]

Glipizide acts by partially blocking potassium channels among beta cells of pancreatic islets of Langerhans. By blocking potassium channels, the cell depolarizes which results in the opening of voltage-gated calcium channels. The resulting calcium influx encourages insulin release from beta cells.

Sulfonylureas may also cause the decrease of serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.[citation needed]


Glipizide synthesis:[1] DE 2012138  U.S. Patent 3,669,966

See also[edit]


  1. ^ Arzneim Forsch. 21,200

External links[edit]